Hormonal
GLP-1 receptor agonist treatment is associated with a statistically significant increase in specific psychiatric adverse events, including nervousness, stress, eating disorders, insomnia, binge eating, fear of eating, and self-induced vomiting, with onset typically occurring within the first 30 days.
If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Trulicity), be aware that psychiatric side effects are a recognized risk, not just a rare anecdote. Symptoms like nervousness, stress, insomnia, and changes in eating behavior (such as bingeing or fear of eating) can start within the first month of treatment. Because these reports are disproportionately high in the database, you should proactively monitor your mental health and mood, especially if you have a history of anxiety or eating disorders, and report any new or worsening symptoms to your prescriber immediately.
Ultimately, based on the full GLP-1 RA psychiatric AE reporting profile, we filtered eight positive signals for psychiatric AEs with ROR05 greater than 1 and defined them as GLP-1 RA-related psychiatric AEs, namely, nervousness... stress... eating disorder... fear of injection... sleep disorder due to general medical condition—insomnia type... binge eating... fear of eating... and self-induced vomiting... which were highly associated with treatment with GLP-1 RAs.
Why this rating
The study uses a large real-world pharmacovigilance database (FAERS) with robust statistical signal detection (ROR), but it is observational and cannot establish causality or incidence rates.
Source
Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database
Wei Chen et al. · Frontiers in Endocrinology · 2024
DOI 10.3389/fendo.2024.1330936
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →